English
简体中文
Total: £ 56.28
Published Date: 2025-11-10 | Pages: 158 | Tables: 147 | Medical Care
The global Drug Metabolism and Pharmacokinetics (DMPK) market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
DMPK is an acronym that stands for drug metabolism and pharmacokinetics. This is a discipline that helps to identify drugs that are likely to be suitable for advancement through the drug development process. It considers how the drug is metabolized and processed by the body.
From a downstream perspective, Biopharmaceutical Companies accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Drug Metabolism and Pharmacokinetics (DMPK) leading manufacturers including Eurofins Discovery, Inotiv, Evotec, Sai Life Sciences, Sygnature Discovery, WuXi AppTec, Hangzhou Tigermed Consulting Co, Q2 Solutions, Jubilant Biosys, Frontage Laboratories, etc., dominate supply; the top five capture approximately % of global revenue, with Eurofins Discovery leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Drug Metabolism and Pharmacokinetics (DMPK) market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Eurofins Discovery
Inotiv
Evotec
Sai Life Sciences
Sygnature Discovery
WuXi AppTec
Hangzhou Tigermed Consulting Co
Q2 Solutions
Jubilant Biosys
Frontage Laboratories
Invitrocue
Creative Biolabs
CrownBioscience
Agilent
H3D
LABCORP
Bioduro-Sundia
Allucent
Segment by Type
Small Molecules
Biologics
Segment by Application
Biopharmaceutical Companies
Government and Academic Institutes
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Drug Metabolism and Pharmacokinetics (DMPK) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Drug Metabolism and Pharmacokinetics (DMPK): Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Small Molecules
1.2.3 Biologics
1.3 Market Segmentation by Application
1.3.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Biopharmaceutical Companies
1.3.3 Government and Academic Institutes
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue Estimates and Forecasts 2020-2031
2.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Small Molecules Market Size by Players
3.3.2 Biologics Market Size by Players
3.4 Global Drug Metabolism and Pharmacokinetics (DMPK) Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Type (2020-2031)
6.4 North America Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Type (2020-2031)
7.4 Europe Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Type (2020-2031)
8.4 Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Type (2020-2031)
9.4 Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Type (2020-2031)
10.4 Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Eurofins Discovery
11.1.1 Eurofins Discovery Corporation Information
11.1.2 Eurofins Discovery Business Overview
11.1.3 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.1.4 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.1.5 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Product in 2024
11.1.6 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Application in 2024
11.1.7 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Geographic Area in 2024
11.1.8 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
11.1.9 Eurofins Discovery Recent Developments
11.2 Inotiv
11.2.1 Inotiv Corporation Information
11.2.2 Inotiv Business Overview
11.2.3 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.2.4 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.2.5 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Product in 2024
11.2.6 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Application in 2024
11.2.7 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Geographic Area in 2024
11.2.8 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
11.2.9 Inotiv Recent Developments
11.3 Evotec
11.3.1 Evotec Corporation Information
11.3.2 Evotec Business Overview
11.3.3 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.3.4 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.3.5 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Product in 2024
11.3.6 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Application in 2024
11.3.7 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Geographic Area in 2024
11.3.8 Evotec Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
11.3.9 Evotec Recent Developments
11.4 Sai Life Sciences
11.4.1 Sai Life Sciences Corporation Information
11.4.2 Sai Life Sciences Business Overview
11.4.3 Sai Life Sciences Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.4.4 Sai Life Sciences Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.4.5 Sai Life Sciences Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Product in 2024
11.4.6 Sai Life Sciences Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Application in 2024
11.4.7 Sai Life Sciences Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Geographic Area in 2024
11.4.8 Sai Life Sciences Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
11.4.9 Sai Life Sciences Recent Developments
11.5 Sygnature Discovery
11.5.1 Sygnature Discovery Corporation Information
11.5.2 Sygnature Discovery Business Overview
11.5.3 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.5.4 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.5.5 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Product in 2024
11.5.6 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Application in 2024
11.5.7 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Geographic Area in 2024
11.5.8 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
11.5.9 Sygnature Discovery Recent Developments
11.6 WuXi AppTec
11.6.1 WuXi AppTec Corporation Information
11.6.2 WuXi AppTec Business Overview
11.6.3 WuXi AppTec Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.6.4 WuXi AppTec Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.6.5 WuXi AppTec Recent Developments
11.7 Hangzhou Tigermed Consulting Co
11.7.1 Hangzhou Tigermed Consulting Co Corporation Information
11.7.2 Hangzhou Tigermed Consulting Co Business Overview
11.7.3 Hangzhou Tigermed Consulting Co Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.7.4 Hangzhou Tigermed Consulting Co Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.7.5 Hangzhou Tigermed Consulting Co Recent Developments
11.8 Q2 Solutions
11.8.1 Q2 Solutions Corporation Information
11.8.2 Q2 Solutions Business Overview
11.8.3 Q2 Solutions Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.8.4 Q2 Solutions Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.8.5 Q2 Solutions Recent Developments
11.9 Jubilant Biosys
11.9.1 Jubilant Biosys Corporation Information
11.9.2 Jubilant Biosys Business Overview
11.9.3 Jubilant Biosys Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.9.4 Jubilant Biosys Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.9.5 Jubilant Biosys Recent Developments
11.10 Frontage Laboratories
11.10.1 Frontage Laboratories Corporation Information
11.10.2 Frontage Laboratories Business Overview
11.10.3 Frontage Laboratories Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.10.4 Frontage Laboratories Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Invitrocue
11.11.1 Invitrocue Corporation Information
11.11.2 Invitrocue Business Overview
11.11.3 Invitrocue Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.11.4 Invitrocue Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.11.5 Invitrocue Recent Developments
11.12 Creative Biolabs
11.12.1 Creative Biolabs Corporation Information
11.12.2 Creative Biolabs Business Overview
11.12.3 Creative Biolabs Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.12.4 Creative Biolabs Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.12.5 Creative Biolabs Recent Developments
11.13 CrownBioscience
11.13.1 CrownBioscience Corporation Information
11.13.2 CrownBioscience Business Overview
11.13.3 CrownBioscience Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.13.4 CrownBioscience Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.13.5 CrownBioscience Recent Developments
11.14 Agilent
11.14.1 Agilent Corporation Information
11.14.2 Agilent Business Overview
11.14.3 Agilent Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.14.4 Agilent Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.14.5 Agilent Recent Developments
11.15 H3D
11.15.1 H3D Corporation Information
11.15.2 H3D Business Overview
11.15.3 H3D Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.15.4 H3D Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.15.5 H3D Recent Developments
11.16 LABCORP
11.16.1 LABCORP Corporation Information
11.16.2 LABCORP Business Overview
11.16.3 LABCORP Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.16.4 LABCORP Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.16.5 LABCORP Recent Developments
11.17 Bioduro-Sundia
11.17.1 Bioduro-Sundia Corporation Information
11.17.2 Bioduro-Sundia Business Overview
11.17.3 Bioduro-Sundia Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.17.4 Bioduro-Sundia Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.17.5 Bioduro-Sundia Recent Developments
11.18 Allucent
11.18.1 Allucent Corporation Information
11.18.2 Allucent Business Overview
11.18.3 Allucent Drug Metabolism and Pharmacokinetics (DMPK) Product Features and Attributes
11.18.4 Allucent Drug Metabolism and Pharmacokinetics (DMPK) Revenue and Gross Margin (2020-2025)
11.18.5 Allucent Recent Developments
12 Drug Metabolism and Pharmacokinetics (DMPK)Industry Chain Analysis
12.1 Drug Metabolism and Pharmacokinetics (DMPK) Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Drug Metabolism and Pharmacokinetics (DMPK) Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Drug Metabolism and Pharmacokinetics (DMPK) Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Drug Metabolism and Pharmacokinetics (DMPK) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Drug Metabolism and Pharmacokinetics (DMPK) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Drug Metabolism and Pharmacokinetics (DMPK) by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drug Metabolism and Pharmacokinetics (DMPK) as of 2024)
Table 11. Global Drug Metabolism and Pharmacokinetics (DMPK) Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Drug Metabolism and Pharmacokinetics (DMPK) Companies Headquarters
Table 13. Global Drug Metabolism and Pharmacokinetics (DMPK) Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue by Application (2026-2031) & (US$ Million)
Table 21. Drug Metabolism and Pharmacokinetics (DMPK) High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Drug Metabolism and Pharmacokinetics (DMPK) Growth Accelerators and Market Barriers
Table 25. North America Drug Metabolism and Pharmacokinetics (DMPK) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Drug Metabolism and Pharmacokinetics (DMPK) Growth Accelerators and Market Barriers
Table 27. Europe Drug Metabolism and Pharmacokinetics (DMPK) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Investment Opportunities and Key Challenges
Table 31. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Eurofins Discovery Corporation Information
Table 35. Eurofins Discovery Description and Major Businesses
Table 36. Eurofins Discovery Product Features and Attributes
Table 37. Eurofins Discovery Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Eurofins Discovery Revenue Proportion by Product in 2024
Table 39. Eurofins Discovery Revenue Proportion by Application in 2024
Table 40. Eurofins Discovery Revenue Proportion by Geographic Area in 2024
Table 41. Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
Table 42. Eurofins Discovery Recent Developments
Table 43. Inotiv Corporation Information
Table 44. Inotiv Description and Major Businesses
Table 45. Inotiv Product Features and Attributes
Table 46. Inotiv Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Inotiv Revenue Proportion by Product in 2024
Table 48. Inotiv Revenue Proportion by Application in 2024
Table 49. Inotiv Revenue Proportion by Geographic Area in 2024
Table 50. Inotiv Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
Table 51. Inotiv Recent Developments
Table 52. Evotec Corporation Information
Table 53. Evotec Description and Major Businesses
Table 54. Evotec Product Features and Attributes
Table 55. Evotec Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Evotec Revenue Proportion by Product in 2024
Table 57. Evotec Revenue Proportion by Application in 2024
Table 58. Evotec Revenue Proportion by Geographic Area in 2024
Table 59. Evotec Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
Table 60. Evotec Recent Developments
Table 61. Sai Life Sciences Corporation Information
Table 62. Sai Life Sciences Description and Major Businesses
Table 63. Sai Life Sciences Product Features and Attributes
Table 64. Sai Life Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Sai Life Sciences Revenue Proportion by Product in 2024
Table 66. Sai Life Sciences Revenue Proportion by Application in 2024
Table 67. Sai Life Sciences Revenue Proportion by Geographic Area in 2024
Table 68. Sai Life Sciences Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
Table 69. Sai Life Sciences Recent Developments
Table 70. Sygnature Discovery Corporation Information
Table 71. Sygnature Discovery Description and Major Businesses
Table 72. Sygnature Discovery Product Features and Attributes
Table 73. Sygnature Discovery Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Sygnature Discovery Revenue Proportion by Product in 2024
Table 75. Sygnature Discovery Revenue Proportion by Application in 2024
Table 76. Sygnature Discovery Revenue Proportion by Geographic Area in 2024
Table 77. Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) SWOT Analysis
Table 78. Sygnature Discovery Recent Developments
Table 79. WuXi AppTec Corporation Information
Table 80. WuXi AppTec Description and Major Businesses
Table 81. WuXi AppTec Product Features and Attributes
Table 82. WuXi AppTec Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. WuXi AppTec Recent Developments
Table 84. Hangzhou Tigermed Consulting Co Corporation Information
Table 85. Hangzhou Tigermed Consulting Co Description and Major Businesses
Table 86. Hangzhou Tigermed Consulting Co Product Features and Attributes
Table 87. Hangzhou Tigermed Consulting Co Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Hangzhou Tigermed Consulting Co Recent Developments
Table 89. Q2 Solutions Corporation Information
Table 90. Q2 Solutions Description and Major Businesses
Table 91. Q2 Solutions Product Features and Attributes
Table 92. Q2 Solutions Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Q2 Solutions Recent Developments
Table 94. Jubilant Biosys Corporation Information
Table 95. Jubilant Biosys Description and Major Businesses
Table 96. Jubilant Biosys Product Features and Attributes
Table 97. Jubilant Biosys Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Jubilant Biosys Recent Developments
Table 99. Frontage Laboratories Corporation Information
Table 100. Frontage Laboratories Description and Major Businesses
Table 101. Frontage Laboratories Product Features and Attributes
Table 102. Frontage Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Frontage Laboratories Recent Developments
Table 104. Invitrocue Corporation Information
Table 105. Invitrocue Description and Major Businesses
Table 106. Invitrocue Product Features and Attributes
Table 107. Invitrocue Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Invitrocue Recent Developments
Table 109. Creative Biolabs Corporation Information
Table 110. Creative Biolabs Description and Major Businesses
Table 111. Creative Biolabs Product Features and Attributes
Table 112. Creative Biolabs Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Creative Biolabs Recent Developments
Table 114. CrownBioscience Corporation Information
Table 115. CrownBioscience Description and Major Businesses
Table 116. CrownBioscience Product Features and Attributes
Table 117. CrownBioscience Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. CrownBioscience Recent Developments
Table 119. Agilent Corporation Information
Table 120. Agilent Description and Major Businesses
Table 121. Agilent Product Features and Attributes
Table 122. Agilent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Agilent Recent Developments
Table 124. H3D Corporation Information
Table 125. H3D Description and Major Businesses
Table 126. H3D Product Features and Attributes
Table 127. H3D Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. H3D Recent Developments
Table 129. LABCORP Corporation Information
Table 130. LABCORP Description and Major Businesses
Table 131. LABCORP Product Features and Attributes
Table 132. LABCORP Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. LABCORP Recent Developments
Table 134. Bioduro-Sundia Corporation Information
Table 135. Bioduro-Sundia Description and Major Businesses
Table 136. Bioduro-Sundia Product Features and Attributes
Table 137. Bioduro-Sundia Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Bioduro-Sundia Recent Developments
Table 139. Allucent Corporation Information
Table 140. Allucent Description and Major Businesses
Table 141. Allucent Product Features and Attributes
Table 142. Allucent Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Allucent Recent Developments
Table 144. Raw Materials Key Suppliers
Table 145. Distributors List
Table 146. Market Trends and Market Evolution
Table 147. Market Drivers and Opportunities
Table 148. Market Challenges, Risks, and Restraints
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
List of Figures
Figure 1. Drug Metabolism and Pharmacokinetics (DMPK) Product Picture
Figure 2. Global Drug Metabolism and Pharmacokinetics (DMPK) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Small Molecules Product Picture
Figure 4. Biologics Product Picture
Figure 5. Global Drug Metabolism and Pharmacokinetics (DMPK) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Biopharmaceutical Companies
Figure 7. Government and Academic Institutes
Figure 8. Others
Figure 9. Drug Metabolism and Pharmacokinetics (DMPK) Report Years Considered
Figure 10. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 12. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue Market Share by Region (2020-2031)
Figure 14. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Small Molecules Revenue Market Share by Player in 2024
Figure 17. Biologics Revenue Market Share by Player in 2024
Figure 18. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue Market Share by Type (2020-2031)
Figure 19. Global Drug Metabolism and Pharmacokinetics (DMPK) Revenue Market Share by Application (2020-2031)
Figure 20. North America Drug Metabolism and Pharmacokinetics (DMPK) Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) in 2024
Figure 22. North America Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Application (2020-2031)
Figure 24. US Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 25. Canada Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 27. Europe Drug Metabolism and Pharmacokinetics (DMPK) Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) in 2024
Figure 29. Europe Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 32. France Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 34. Italy Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 35. Russia Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 41. Japan Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 43. Australia Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 44. India Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) in 2024
Figure 52. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) in 2024
Figure 58. South America Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa Drug Metabolism and Pharmacokinetics (DMPK) Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2025) & (US$ Million)
Figure 61. Israel Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa Drug Metabolism and Pharmacokinetics (DMPK) Revenue (2020-2025) & (US$ Million)
Figure 64. Drug Metabolism and Pharmacokinetics (DMPK) Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
